Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Dec 1;31(6):579-581.
doi: 10.1097/CMR.0000000000000775.

Nivolumab exposure in a hemodialysis patient with metastatic melanoma

Judith L Gulikers  1   2 , Sander Croes  1   2 , Marco J W Schreurs  3 , Elisabeth J R Litjens  4 , Maureen J B Aarts  5 , Robin M J M van Geel  1   2
Affiliations
Case Reports

Nivolumab exposure in a hemodialysis patient with metastatic melanoma

Judith L Gulikers et al. Melanoma Res. .

Abstract

The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three times a week, treated with 480 mg nivolumab every 4 weeks. A serum trough concentration of nivolumab was determined before the start of the third cycle, and two samples were taken immediately before and after a hemodialysis session during this cycle. All nivolumab serum concentrations were within a similar range as those previously measured among patients without renal insufficiency, after a comparable duration of nivolumab treatment. Therefore, we conclude that IHD does not influence nivolumab exposure. Furthermore, nivolumab treatment was continued without complications and appears to be well tolerated for patients on IHD.

PubMed Disclaimer

References

    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320–330.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
    1. Sood S, Jayachandiran R, Pandey S. Current advancements and novel strategies in the treatment of metastatic melanoma. Integr Cancer Ther 2021; 20:1534735421990078.
    1. AusPAR-TGA. Australian public assessment report for nivolumab. 2020.Department of Health, Australian Government;
    1. Brystol-Myers Squibb. Opdivo Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-p... . [Accessed 18 March 2021].

Publication types